These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

965 related articles for article (PubMed ID: 30665053)

  • 1. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phases 0, 1 and 2 oncology clinical trials: current questions].
    Penel N; Fournier C; Stéphanie C
    Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to improve the clinical development paradigm and its division into phases I, II and III.
    Bamberger M; Moore N; Lechat P;
    Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
    Feinberg J; Japour AJ
    Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
    Mistry P; Dunn JA; Marshall A
    BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations.
    Hurria A; Dale W; Mooney M; Rowland JH; Ballman KV; Cohen HJ; Muss HB; Schilsky RL; Ferrell B; Extermann M; Schmader KE; Mohile SG;
    J Clin Oncol; 2014 Aug; 32(24):2587-94. PubMed ID: 25071116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial designs for targeted agents.
    Ma BB; Britten CD; Siu LL
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1287-305. PubMed ID: 12512393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethics of Pharma Clinical Trials in the Era of Precision Oncology.
    Turner JH
    Cancer Biother Radiopharm; 2021 Feb; 36(1):1-9. PubMed ID: 32935997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim analyses in clinical trials: why do we plan them?
    Fossâ SD; Skovlund E
    J Clin Oncol; 2000 Dec; 18(24):4007-8. PubMed ID: 11118460
    [No Abstract]   [Full Text] [Related]  

  • 13. Ethical considerations of neuro-oncology trial design in the era of precision medicine.
    Gupta S; Smith TR; Broekman ML
    J Neurooncol; 2017 Aug; 134(1):1-7. PubMed ID: 28555425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics.
    Drugs R D; 2004; 5(5):293-6. PubMed ID: 15357628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
    Simon R
    Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
    Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
    Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
    Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.